A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer.

Symonds L, Jenkins I, Linden HM, Kurland B, Gralow JR, Gadi VVK, Ellis GK, Wu Q, Rodler E, Chalasani P, Chai X, Riedel J, Scca Network Investigators, Stopeck A, Brown-Glaberman U, Specht JM

Open source

DOI
10.1016/j.clbc.2021.05.009
Published
2022 Jan
Container
Clinical breast cancer
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.clbc.2021.05.009,
  title = {A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer.},
  author = {Symonds L and Jenkins I and Linden HM and Kurland B and Gralow JR and Gadi VVK and Ellis GK and Wu Q and Rodler E and Chalasani P and Chai X and Riedel J and Scca Network Investigators and Stopeck A and Brown-Glaberman U and Specht JM},
  year = {2022},
  journal = {Clinical breast cancer},
  doi = {10.1016/j.clbc.2021.05.009},
  url = {https://doi.org/10.1016/j.clbc.2021.05.009}
}

RIS

TY  - JOUR
TI  - A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer.
AU  - Symonds L
AU  - Jenkins I
AU  - Linden HM
AU  - Kurland B
AU  - Gralow JR
AU  - Gadi VVK
AU  - Ellis GK
AU  - Wu Q
AU  - Rodler E
AU  - Chalasani P
AU  - Chai X
AU  - Riedel J
AU  - Scca Network Investigators
AU  - Stopeck A
AU  - Brown-Glaberman U
AU  - Specht JM
PY  - 2022
JO  - Clinical breast cancer
DO  - 10.1016/j.clbc.2021.05.009
UR  - https://doi.org/10.1016/j.clbc.2021.05.009
ER  - 

APA

L, S., I, J., HM, L., B, K., JR, G., VVK, G., GK, E., Q, W., E, R., P, C., X, C., J, R., Investigators, S. N., A, S., U, B., & JM, S. (2022). A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer.. Clinical breast cancer. https://doi.org/10.1016/j.clbc.2021.05.009

Source records